Abstract
Opioids are commonly used analgesics in clinical practice. Three opioid receptors (μ, δ and κ) that mediate opioid effects have been identified by molecular cloning. Each type of opioid receptors consists of subtypes of receptors as suggested by pharmacological studies. Although μ opioid receptors are the major receptor to mediate the analgesic effects of opioids, δ and κ receptors are also important in anti-nociception (for example, δ and κ receptors can mediate spinal analgesia). Recently, the cytoprotective effects of opioids have been recognized. The presence of opioids during harmful events such as ischemia reduces cell injury in multiple organs including heart and brain. These effects appear to be mediated by δ receptors in most studies. A new form of cytoprotection in which a prior exposure to opioids renders protection against cell ischemia (opioid preconditioning) has been identified. In the heart, this opioid preconditioning-induced protection has
Keywords: opioids, opioid receptors, analgesia, ischemia-reperfusion injury, cardioprotection, neuroprotection, preconditioning
Current Pharmaceutical Design
Title: Opioids: Old Drugs for Potential New Applications
Volume: 11 Issue: 10
Author(s): U. Barry and Z. Zuo
Affiliation:
Keywords: opioids, opioid receptors, analgesia, ischemia-reperfusion injury, cardioprotection, neuroprotection, preconditioning
Abstract: Opioids are commonly used analgesics in clinical practice. Three opioid receptors (μ, δ and κ) that mediate opioid effects have been identified by molecular cloning. Each type of opioid receptors consists of subtypes of receptors as suggested by pharmacological studies. Although μ opioid receptors are the major receptor to mediate the analgesic effects of opioids, δ and κ receptors are also important in anti-nociception (for example, δ and κ receptors can mediate spinal analgesia). Recently, the cytoprotective effects of opioids have been recognized. The presence of opioids during harmful events such as ischemia reduces cell injury in multiple organs including heart and brain. These effects appear to be mediated by δ receptors in most studies. A new form of cytoprotection in which a prior exposure to opioids renders protection against cell ischemia (opioid preconditioning) has been identified. In the heart, this opioid preconditioning-induced protection has
Export Options
About this article
Cite this article as:
Barry U. and Zuo Z., Opioids: Old Drugs for Potential New Applications, Current Pharmaceutical Design 2005; 11 (10) . https://dx.doi.org/10.2174/1381612053507459
DOI https://dx.doi.org/10.2174/1381612053507459 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Adrenalectomy on Protective Effects of Urocortin I, a Corticotropin-Releasing Factor, Against Indomethacin-Induced Enteropathy in Rats
Current Neuropharmacology Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions
Cardiovascular & Hematological Disorders-Drug Targets Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Acute Kidney Injury: Turning the Tide
Current Drug Targets Proteasomal Inhibition: A Novel Pathway for Prevention of Atherosclerosis and Restenosis
Vascular Disease Prevention (Discontinued) Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets Human Use of Leucoselect® Phytosome® with Special Reference to Inflammatory- Allergic Pathologies in Frail Elderly Patients
Current Pharmaceutical Design Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Potential Mechanisms of Cancer Chemoprevention by Anthocyanins
Current Molecular Medicine Evaluation of Early Regenerative Processes in a Preclinical Pig Model of Acute Kidney Injury
Current Molecular Medicine Recent Progress in Therapeutic and Diagnostic Applications of Lanthanides
Mini-Reviews in Medicinal Chemistry Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Analysis of Hypoxiamir-Gene Regulatory Network Identifies Critical MiRNAs Influencing Cell-Cycle Regulation Under Hypoxic Conditions
MicroRNA Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology